Adicet Bio
Yahoo Finance • 2 years ago
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
REDWOOD CITY, Calif. & BOSTON, February 01, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that... Full story
Yahoo Finance • 2 years ago
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
REDWOOD CITY, Calif. & BOSTON, November 30, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that... Full story
Yahoo Finance • 2 years ago
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual Meeting Company to host ADI-001 webcast event on Decem... Full story
Yahoo Finance • 3 years ago
Adicet Bio to Present at Upcoming Investor Conferences
MENLO PARK, Calif. & BOSTON, May 18, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell the... Full story
Yahoo Finance • 3 years ago
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.9 million in cash and cash equivalents as of March 31, 2022 MENLO PARK, Calif. & BOSTON, May 12, 2022--(BUS... Full story
Yahoo Finance • 3 years ago
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma delta CAR T cells demon... Full story
Yahoo Finance • 3 years ago
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
MENLO PARK, Calif. & BOSTON, April 27, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell t... Full story
Yahoo Finance • 3 years ago
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif., April 07, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies... Full story
Yahoo Finance • 3 years ago
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. & BOSTON, April 01, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement... Full story
